25 XP   0   0   10

Duopharma Biotech Bhd
Buy, Hold or Sell?

Let's analyse Duopharma Biotech Bhd together

PenkeI guess you are interested in Duopharma Biotech Bhd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Duopharma Biotech Bhd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Duopharma Biotech Bhd

I send you an email if I find something interesting about Duopharma Biotech Bhd.

Quick analysis of Duopharma Biotech Bhd (30 sec.)










What can you expect buying and holding a share of Duopharma Biotech Bhd? (30 sec.)

How much money do you get?

How much money do you get?
RM0.00
When do you have the money?
1 year
How often do you get paid?
42.5%

What is your share worth?

Current worth
RM0.71
Expected worth in 1 year
RM0.75
How sure are you?
82.5%

+ What do you gain per year?

Total Gains per Share
RM0.05
Return On Investment
3.9%

For what price can you sell your share?

Current Price per Share
RM1.19
Expected price per share
RM1.0813 - RM1.17
How sure are you?
50%

1. Valuation of Duopharma Biotech Bhd (5 min.)




Live pricePrice per Share (EOD)

RM1.19

Intrinsic Value Per Share

RM0.13 - RM2.40

Total Value Per Share

RM0.84 - RM3.11

2. Growth of Duopharma Biotech Bhd (5 min.)




Is Duopharma Biotech Bhd growing?

Current yearPrevious yearGrowGrow %
How rich?$143.8m$134.6m$6.8m4.9%

How much money is Duopharma Biotech Bhd making?

Current yearPrevious yearGrowGrow %
Making money$2.7m$3.6m-$914.3k-33.2%
Net Profit Margin7.3%10.1%--

How much money comes from the company's main activities?

3. Financial Health of Duopharma Biotech Bhd (5 min.)




What can you expect buying and holding a share of Duopharma Biotech Bhd? (5 min.)

Welcome investor! Duopharma Biotech Bhd's management wants to use your money to grow the business. In return you get a share of Duopharma Biotech Bhd.

What can you expect buying and holding a share of Duopharma Biotech Bhd?

First you should know what it really means to hold a share of Duopharma Biotech Bhd. And how you can make/lose money.

Speculation

The Price per Share of Duopharma Biotech Bhd is RM1.19. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Duopharma Biotech Bhd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Duopharma Biotech Bhd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is RM0.71. Based on the TTM, the Book Value Change Per Share is RM0.01 per quarter. Based on the YOY, the Book Value Change Per Share is RM0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is RM0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Duopharma Biotech Bhd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 RM% of Price per ShareRM% of Price per ShareRM% of Price per ShareRM% of Price per ShareRM% of Price per Share
Usd Eps0.000.2%0.000.2%0.000.3%0.000.3%0.000.2%
Usd Book Value Change Per Share0.000.2%0.000.1%0.000.1%0.000.2%0.000.2%
Usd Dividend Per Share0.000.0%0.000.1%0.000.0%0.000.1%0.000.1%
Usd Total Gains Per Share0.000.2%0.000.2%0.000.2%0.000.3%0.000.3%
Usd Price Per Share0.26-0.28-0.29-0.37-0.43-
Price to Earnings Ratio35.64-27.33-19.26-28.68-47.98-
Price-to-Total Gains Ratio96.17-132.81-142.58-139.39-96.19-
Price to Book Ratio1.76-1.89-2.09-2.79-5.21-
Price-to-Total Gains Ratio96.17-132.81-142.58-139.39-96.19-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.249186
Number of shares4013
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (4013 shares)9.7812.58
Gains per Year (4013 shares)39.1350.33
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1112829143640
2235668297290
3348410743108140
44511114657144190
55613918572180240
66816722486216290
779195263100252340
890223302115288390
9101251341129324440
10113279380143360490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%48.00.00.0100.0%
Book Value Change Per Share4.00.00.0100.0%9.03.00.075.0%17.03.00.085.0%31.09.00.077.5%37.011.00.077.1%
Dividend per Share3.00.01.075.0%9.00.03.075.0%12.00.08.060.0%17.00.023.042.5%19.00.029.039.6%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%33.07.00.082.5%39.09.00.081.3%

Fundamentals of Duopharma Biotech Bhd

About Duopharma Biotech Bhd

Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others. The company's product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol. The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands. In addition, it offers property management and services; and distributes, imports, and exports chemical products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.

Fundamental data was last updated by Penke on 2024-04-20 11:03:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Duopharma Biotech Bhd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Duopharma Biotech Bhd earns for each RM1 of revenue.

  • Above 10% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 5.1% means that RM0.05 for each RM1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Duopharma Biotech Bhd:

  • The MRQ is 5.1%. The company is making a profit. +1
  • The TTM is 7.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ5.1%TTM7.3%-2.2%
TTM7.3%YOY10.1%-2.8%
TTM7.3%5Y9.5%-2.2%
5Y9.5%10Y10.9%-1.4%
1.1.2. Return on Assets

Shows how efficient Duopharma Biotech Bhd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.6% Return on Assets means that Duopharma Biotech Bhd generated RM0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Duopharma Biotech Bhd:

  • The MRQ is 0.6%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.0%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.6%TTM1.0%-0.4%
TTM1.0%YOY1.4%-0.4%
TTM1.0%5Y1.4%-0.4%
5Y1.4%10Y1.7%-0.3%
1.1.3. Return on Equity

Shows how efficient Duopharma Biotech Bhd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.2% Return on Equity means Duopharma Biotech Bhd generated RM0.01 for each RM1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Duopharma Biotech Bhd:

  • The MRQ is 1.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.2%TTM2.0%-0.7%
TTM2.0%YOY2.7%-0.8%
TTM2.0%5Y2.5%-0.5%
5Y2.5%10Y2.6%-0.1%

1.2. Operating Efficiency of Duopharma Biotech Bhd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Duopharma Biotech Bhd is operating .

  • Measures how much profit Duopharma Biotech Bhd makes for each RM1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 6.3% means the company generated RM0.06  for each RM1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Duopharma Biotech Bhd:

  • The MRQ is 6.3%. The company is operating less efficient.
  • The TTM is 11.0%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ6.3%TTM11.0%-4.7%
TTM11.0%YOY13.2%-2.2%
TTM11.0%5Y13.3%-2.2%
5Y13.3%10Y15.0%-1.7%
1.2.2. Operating Ratio

Measures how efficient Duopharma Biotech Bhd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.94 means that the operating costs are RM0.94 for each RM1 in net sales.

Let's take a look of the Operating Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.937. The company is less efficient in keeping operating costs low.
  • The TTM is 0.891. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.937TTM0.891+0.046
TTM0.891YOY0.869+0.022
TTM0.8915Y0.869+0.022
5Y0.86910Y0.854+0.015

1.3. Liquidity of Duopharma Biotech Bhd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Duopharma Biotech Bhd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.09 means the company has RM4.09 in assets for each RM1 in short-term debts.

Let's take a look of the Current Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 4.086. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.564. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ4.086TTM2.564+1.522
TTM2.564YOY2.137+0.427
TTM2.5645Y2.186+0.378
5Y2.18610Y2.733-0.548
1.3.2. Quick Ratio

Measures if Duopharma Biotech Bhd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 3.60 means the company can pay off RM3.60 for each RM1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 3.597. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.811. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.597TTM1.811+1.786
TTM1.811YOY1.266+0.545
TTM1.8115Y1.325+0.486
5Y1.32510Y1.216+0.109

1.4. Solvency of Duopharma Biotech Bhd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Duopharma Biotech Bhd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Duopharma Biotech Bhd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.49 means that Duopharma Biotech Bhd assets are financed with 48.9% credit (debt) and the remaining percentage (100% - 48.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.489. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.481. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.489TTM0.481+0.008
TTM0.481YOY0.469+0.012
TTM0.4815Y0.450+0.031
5Y0.45010Y0.377+0.073
1.4.2. Debt to Equity Ratio

Measures if Duopharma Biotech Bhd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 95.8% means that company has RM0.96 debt for each RM1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.958. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.930. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.958TTM0.930+0.028
TTM0.930YOY0.884+0.046
TTM0.9305Y0.824+0.106
5Y0.82410Y0.659+0.165

2. Market Valuation of Duopharma Biotech Bhd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every RM1 in earnings Duopharma Biotech Bhd generates.

  • Above 15 is considered overpriced but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 35.64 means the investor is paying RM35.64 for every RM1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 33.660. Based on the earnings, the company is overpriced. -1
  • The MRQ is 35.640. Based on the earnings, the company is overpriced. -1
  • The TTM is 27.329. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD33.660MRQ35.640-1.980
MRQ35.640TTM27.329+8.311
TTM27.329YOY19.259+8.070
TTM27.3295Y28.685-1.356
5Y28.68510Y47.976-19.292
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 9.050. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 9.583. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 39.167. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD9.050MRQ9.583-0.532
MRQ9.583TTM39.167-29.584
TTM39.167YOY-56.463+95.629
TTM39.1675Y-240.202+279.369
5Y-240.20210Y-186.990-53.212
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Duopharma Biotech Bhd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 1.666. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.764. Based on the equity, the company is underpriced. +1
  • The TTM is 1.894. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.666MRQ1.764-0.098
MRQ1.764TTM1.894-0.130
TTM1.894YOY2.093-0.199
TTM1.8945Y2.794-0.901
5Y2.79410Y5.209-2.414
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Duopharma Biotech Bhd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0130.008+58%0.008+61%0.011+22%0.0130%
Book Value Per Share--0.7140.703+2%0.669+7%0.633+13%0.516+38%
Current Ratio--4.0862.564+59%2.137+91%2.186+87%2.733+49%
Debt To Asset Ratio--0.4890.481+2%0.469+4%0.450+9%0.377+30%
Debt To Equity Ratio--0.9580.930+3%0.884+8%0.824+16%0.659+45%
Dividend Per Share---0.003-100%0.002-100%0.004-100%0.003-100%
Eps--0.0090.014-35%0.018-51%0.016-44%0.013-31%
Free Cash Flow Per Share--0.0330.003+1079%0.000+101%-0.003+108%-0.004+113%
Free Cash Flow To Equity Per Share---0.0120.031-138%0.005-361%0.009-233%0.011-207%
Gross Profit Margin--1.000-0.532+153%-0.534+153%-0.496+150%-0.533+153%
Intrinsic Value_10Y_max--2.398--------
Intrinsic Value_10Y_min--0.129--------
Intrinsic Value_1Y_max--0.021--------
Intrinsic Value_1Y_min---0.016--------
Intrinsic Value_3Y_max--0.229--------
Intrinsic Value_3Y_min---0.023--------
Intrinsic Value_5Y_max--0.640--------
Intrinsic Value_5Y_min---0.003--------
Market Cap1144710999.040-6%1212046940.1601279382881.280-5%1346718822.400-10%1693498919.168-28%1994820041.115-39%
Net Profit Margin--0.0510.073-30%0.101-50%0.095-47%0.109-53%
Operating Margin--0.0630.110-43%0.132-52%0.133-52%0.150-58%
Operating Ratio--0.9370.891+5%0.869+8%0.869+8%0.854+10%
Pb Ratio1.666-6%1.7641.894-7%2.093-16%2.794-37%5.209-66%
Pe Ratio33.660-6%35.64027.329+30%19.259+85%28.685+24%47.976-26%
Price Per Share1.190-6%1.2601.330-5%1.400-10%1.761-28%2.074-39%
Price To Free Cash Flow Ratio9.050-6%9.58339.167-76%-56.463+689%-240.202+2607%-186.990+2051%
Price To Total Gains Ratio90.828-6%96.171132.805-28%142.584-33%139.395-31%96.1880%
Quick Ratio--3.5971.811+99%1.266+184%1.325+171%1.216+196%
Return On Assets--0.0060.010-38%0.014-56%0.014-54%0.017-63%
Return On Equity--0.0120.020-37%0.027-55%0.025-51%0.026-53%
Total Gains Per Share--0.0130.012+13%0.010+28%0.015-12%0.016-20%
Usd Book Value--143883556.200141574659.450+2%134685137.700+7%127413125.910+13%103997918.445+38%
Usd Book Value Change Per Share--0.0030.002+58%0.002+61%0.002+22%0.0030%
Usd Book Value Per Share--0.1500.147+2%0.140+7%0.132+13%0.108+38%
Usd Dividend Per Share---0.001-100%0.000-100%0.001-100%0.001-100%
Usd Eps--0.0020.003-35%0.004-51%0.003-44%0.003-31%
Usd Free Cash Flow--6621437.400561401.400+1079%-39576.600+101%-523855.980+108%-833323.005+113%
Usd Free Cash Flow Per Share--0.0070.001+1079%0.000+101%-0.001+108%-0.001+113%
Usd Free Cash Flow To Equity Per Share---0.0020.006-138%0.001-361%0.002-233%0.002-207%
Usd Market Cap239702483.199-6%253802629.270267902775.340-5%282002921.411-10%354618673.674-28%417715316.609-39%
Usd Price Per Share0.249-6%0.2640.279-5%0.293-10%0.369-28%0.434-39%
Usd Profit--1780318.8002756018.100-35%3670363.200-51%3165332.280-44%2569887.675-31%
Usd Revenue--35074709.40036892458.450-5%36473134.950-4%33367712.010+5%25721580.945+36%
Usd Total Gains Per Share--0.0030.002+13%0.002+28%0.003-12%0.003-20%
 EOD+4 -4MRQTTM+16 -20YOY+15 -215Y+14 -2210Y+13 -23

3.2. Fundamental Score

Let's check the fundamental score of Duopharma Biotech Bhd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1533.660
Price to Book Ratio (EOD)Between0-11.666
Net Profit Margin (MRQ)Greater than00.051
Operating Margin (MRQ)Greater than00.063
Quick Ratio (MRQ)Greater than13.597
Current Ratio (MRQ)Greater than14.086
Debt to Asset Ratio (MRQ)Less than10.489
Debt to Equity Ratio (MRQ)Less than10.958
Return on Equity (MRQ)Greater than0.150.012
Return on Assets (MRQ)Greater than0.050.006
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Duopharma Biotech Bhd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.125
Ma 20Greater thanMa 501.186
Ma 50Greater thanMa 1001.194
Ma 100Greater thanMa 2001.214
OpenGreater thanClose1.160
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Short-term Investments  -1,0500-1,0500-1,0500-1,050162,845161,795



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets1,345,135
Total Liabilities658,012
Total Stockholder Equity687,123
 As reported
Total Liabilities 658,012
Total Stockholder Equity+ 687,123
Total Assets = 1,345,135

Assets

Total Assets1,345,135
Total Current Assets679,451
Long-term Assets665,684
Total Current Assets
Cash And Cash Equivalents 108,707
Short-term Investments 161,795
Net Receivables 165,881
Inventory 243,068
Total Current Assets  (as reported)679,451
Total Current Assets  (calculated)679,451
+/-0
Long-term Assets
Property Plant Equipment 579,979
Long-term Assets Other 38,802
Long-term Assets  (as reported)665,684
Long-term Assets  (calculated)618,781
+/- 46,903

Liabilities & Shareholders' Equity

Total Current Liabilities166,305
Long-term Liabilities491,707
Total Stockholder Equity687,123
Total Current Liabilities
Short-term Debt 65,546
Accounts payable 100,392
Other Current Liabilities 367
Total Current Liabilities  (as reported)166,305
Total Current Liabilities  (calculated)166,305
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)491,707
Long-term Liabilities  (calculated)0
+/- 491,707
Total Stockholder Equity
Common Stock432,466
Retained Earnings 319,065
Accumulated Other Comprehensive Income -64,408
Total Stockholder Equity (as reported)687,123
Total Stockholder Equity (calculated)687,123
+/-0
Other
Cash and Short Term Investments 270,502
Common Stock Shares Outstanding 961,942
Liabilities and Stockholders Equity 1,345,135
Net Debt 437,741
Net Working Capital 513,146
Short Long Term Debt Total 546,448



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-31
> Total Assets 
201,782
197,931
195,539
198,030
203,809
213,667
217,013
205,652
225,811
218,296
227,022
222,477
239,183
541,930
660,529
633,446
642,424
632,404
639,069
661,463
694,557
689,041
711,265
705,240
745,045
802,944
835,128
836,378
875,922
910,726
907,542
919,801
959,496
1,007,333
997,257
1,058,432
1,105,955
1,096,800
1,179,185
1,164,131
1,203,979
1,204,377
1,216,686
1,221,919
1,242,074
1,248,792
1,383,502
1,345,135
1,345,1351,383,5021,248,7921,242,0741,221,9191,216,6861,204,3771,203,9791,164,1311,179,1851,096,8001,105,9551,058,432997,2571,007,333959,496919,801907,542910,726875,922836,378835,128802,944745,045705,240711,265689,041694,557661,463639,069632,404642,424633,446660,529541,930239,183222,477227,022218,296225,811205,652217,013213,667203,809198,030195,539197,931201,782
   > Total Current Assets 
100,895
94,283
93,140
92,620
100,271
104,410
105,821
94,188
112,077
104,145
113,226
106,854
119,497
268,193
383,497
354,346
362,345
351,875
358,035
365,182
386,552
377,126
378,229
356,619
385,017
391,482
395,610
367,330
396,476
431,540
429,803
417,205
452,220
486,727
444,683
459,693
510,357
458,509
536,337
494,796
526,260
529,583
544,339
541,487
565,411
575,987
716,548
679,451
679,451716,548575,987565,411541,487544,339529,583526,260494,796536,337458,509510,357459,693444,683486,727452,220417,205429,803431,540396,476367,330395,610391,482385,017356,619378,229377,126386,552365,182358,035351,875362,345354,346383,497268,193119,497106,854113,226104,145112,07794,188105,821104,410100,27192,62093,14094,283100,895
       Cash And Cash Equivalents 
11,024
1,846
4,777
14,139
18,443
20,311
19,580
18,879
18,028
6,805
15,859
18,303
30,485
31,320
142,797
143,510
146,900
122,574
132,326
114,814
111,651
82,917
86,800
96,021
76,749
77,211
94,073
98,254
73,967
96,170
92,123
120,669
126,726
163,674
129,965
158,029
149,270
109,073
109,696
137,980
152,548
143,600
142,385
157,637
127,880
135,565
281,884
108,707
108,707281,884135,565127,880157,637142,385143,600152,548137,980109,696109,073149,270158,029129,965163,674126,726120,66992,12396,17073,96798,25494,07377,21176,74996,02186,80082,917111,651114,814132,326122,574146,900143,510142,79731,32030,48518,30315,8596,80518,02818,87919,58020,31118,44314,1394,7771,84611,024
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,050
-1,050
-1,050
-1,050
161,795
161,795-1,050-1,050-1,050-1,0500000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
121,000
120,000
102,000
99,000
0
0
0
0
0
0
0
0
0
0
0
0
0
176,957
145,938
187,705
164,562
152,393
142,181
181,139
161,253
185,002
130,495
167,850
177,078
184,840
142,152
192,769
186,236
182,271
165,881
165,881182,271186,236192,769142,152184,840177,078167,850130,495185,002161,253181,139142,181152,393164,562187,705145,938176,957000000000000099,000102,000120,000121,0000000000000000
       Inventory 
43,500
46,797
47,558
41,383
39,614
39,783
36,758
36,331
52,961
55,682
52,077
44,644
45,736
116,145
121,055
103,467
116,429
121,427
122,717
139,101
143,068
146,761
152,718
136,303
131,394
137,595
139,498
139,607
144,444
152,261
158,656
144,003
130,302
148,792
152,870
151,266
175,925
184,903
238,931
222,192
203,153
206,916
213,485
235,179
244,762
254,186
252,393
243,068
243,068252,393254,186244,762235,179213,485206,916203,153222,192238,931184,903175,925151,266152,870148,792130,302144,003158,656152,261144,444139,607139,498137,595131,394136,303152,718146,761143,068139,101122,717121,427116,429103,467121,055116,14545,73644,64452,07755,68252,96136,33136,75839,78339,61441,38347,55846,79743,500
       Other Current Assets 
46,371
45,640
40,805
37,098
42,214
44,316
49,483
38,978
41,088
41,658
45,290
43,907
43,276
120,728
119,645
107,369
99,016
107,874
102,992
111,267
131,833
147,448
138,711
124,295
176,874
176,676
162,039
129,469
178,065
183,109
179,024
152,533
195,192
174,261
161,848
150,398
185,162
164,533
187,710
134,624
170,559
179,067
188,469
6,519
0
0
0
0
00006,519188,469179,067170,559134,624187,710164,533185,162150,398161,848174,261195,192152,533179,024183,109178,065129,469162,039176,676176,874124,295138,711147,448131,833111,267102,992107,87499,016107,369119,645120,72843,27643,90745,29041,65841,08838,97849,48344,31642,21437,09840,80545,64046,371
   > Long-term Assets 
100,887
103,648
102,399
105,410
103,538
109,257
111,192
111,464
113,734
114,151
113,796
115,623
119,686
273,737
277,032
279,100
280,079
280,529
281,034
296,281
308,005
311,915
333,036
348,621
360,028
411,462
439,518
469,048
479,446
479,186
477,739
502,596
507,276
520,606
552,574
598,739
595,598
638,291
642,848
669,335
677,719
674,794
672,347
680,432
676,663
672,805
666,954
665,684
665,684666,954672,805676,663680,432672,347674,794677,719669,335642,848638,291595,598598,739552,574520,606507,276502,596477,739479,186479,446469,048439,518411,462360,028348,621333,036311,915308,005296,281281,034280,529280,079279,100277,032273,737119,686115,623113,796114,151113,734111,464111,192109,257103,538105,410102,399103,648100,887
       Property Plant Equipment 
95,167
97,928
96,679
98,940
97,068
98,102
99,692
98,902
101,096
100,859
100,106
101,060
104,600
248,585
250,413
269,290
267,604
269,401
269,231
276,241
286,952
289,205
306,688
321,335
335,231
338,175
360,453
386,182
394,041
401,928
404,264
412,248
416,060
424,708
432,013
441,789
460,174
501,672
521,520
542,525
559,559
564,741
569,238
579,919
581,813
577,724
573,884
579,979
579,979573,884577,724581,813579,919569,238564,741559,559542,525521,520501,672460,174441,789432,013424,708416,060412,248404,264401,928394,041386,182360,453338,175335,231321,335306,688289,205286,952276,241269,231269,401267,604269,290250,413248,585104,600101,060100,106100,859101,09698,90299,69298,10297,06898,94096,67997,92895,167
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,235
0
0
0
19,403
0
0
0
28,113
29,999
29,263
29,361
35,066
35,530
34,957
34,341
39,524
39,062
38,865
38,729
43,980
47,977
47,811
47,801
0
047,80147,81147,97743,98038,72938,86539,06239,52434,34134,95735,53035,06629,36129,26329,99928,11300019,40300016,23500000000000000000000000
       Long-term Assets Other 
5,720
5,720
5,720
6,470
6,470
11,155
11,500
11,500
11,500
11,500
11,500
11,500
11,500
13,300
13,300
1,000
1,000
1,000
1,000
1,000
1,000
1,000
0
1,200
1,200
45,513
50,913
53,263
55,646
47,759
42,432
53,039
51,590
56,271
80,812
113,347
91,070
93,179
78,761
74,586
65,567
55,132
49,066
43,201
34,383
35,921
33,841
38,802
38,80233,84135,92134,38343,20149,06655,13265,56774,58678,76193,17991,070113,34780,81256,27151,59053,03942,43247,75955,64653,26350,91345,5131,2001,20001,0001,0001,0001,0001,0001,0001,00013,30013,30011,50011,50011,50011,50011,50011,50011,50011,1556,4706,4705,7205,7205,720
> Total Liabilities 
30,629
35,008
26,174
27,527
26,606
25,775
36,910
23,003
34,797
38,496
38,539
28,847
34,420
351,687
212,347
183,728
184,863
185,683
186,007
206,947
230,175
226,466
237,285
225,375
254,398
316,669
335,052
355,337
377,828
406,994
399,126
390,051
418,454
423,391
402,836
414,611
467,172
482,957
566,849
540,127
568,508
566,271
572,703
566,697
573,233
574,889
708,982
658,012
658,012708,982574,889573,233566,697572,703566,271568,508540,127566,849482,957467,172414,611402,836423,391418,454390,051399,126406,994377,828355,337335,052316,669254,398225,375237,285226,466230,175206,947186,007185,683184,863183,728212,347351,68734,42028,84738,53938,49634,79723,00336,91025,77526,60627,52726,17435,00830,629
   > Total Current Liabilities 
25,477
29,856
21,022
21,868
21,198
20,558
31,742
18,554
31,201
34,970
33,901
23,347
28,921
230,029
90,638
74,712
75,820
77,117
87,067
103,156
128,266
134,644
140,244
121,659
149,834
188,149
186,213
222,445
244,949
265,496
248,158
239,442
263,741
266,381
182,965
150,321
198,873
196,426
253,798
230,309
240,686
240,187
258,126
264,591
277,757
290,407
333,065
166,305
166,305333,065290,407277,757264,591258,126240,187240,686230,309253,798196,426198,873150,321182,965266,381263,741239,442248,158265,496244,949222,445186,213188,149149,834121,659140,244134,644128,266103,15687,06777,11775,82074,71290,638230,02928,92123,34733,90134,97031,20118,55431,74220,55821,19821,86821,02229,85625,477
       Short-term Debt 
8,332
6,248
4,165
5,000
5,000
0
6,000
0
0
10,000
10,000
0
0
152,780
11,760
18,947
18,252
11,570
25,006
21,498
35,112
32,763
28,301
36,291
59,223
86,033
86,034
121,842
124,338
130,571
124,601
125,441
131,705
131,686
55,486
49,394
63,279
65,451
106,107
103,566
102,097
101,121
117,892
135,081
149,793
162,674
227,154
65,546
65,546227,154162,674149,793135,081117,892101,121102,097103,566106,10765,45163,27949,39455,486131,686131,705125,441124,601130,571124,338121,84286,03486,03359,22336,29128,30132,76335,11221,49825,00611,57018,25218,94711,760152,7800010,00010,000006,00005,0005,0004,1656,2488,332
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
265,000
124,000
123,000
122,000
0
0
0
0
0
0
0
0
0
0
0
0
0
124,601
124,663
131,705
131,686
55,486
48,793
63,279
65,451
106,107
102,925
102,097
101,121
117,892
134,141
149,793
162,674
227,154
0
0227,154162,674149,793134,141117,892101,121102,097102,925106,10765,45163,27948,79355,486131,686131,705124,663124,6010000000000000122,000123,000124,000265,0000000000000000
       Accounts payable 
15,714
22,536
15,045
16,822
14,454
14,222
16,266
17,159
27,491
18,155
18,855
21,624
21,215
64,473
64,382
55,765
53,032
46,295
42,665
0
71,262
77,450
87,807
19,055
66,003
75,846
85,306
31,202
119,979
134,560
123,141
34,670
131,223
132,346
125,854
22,933
134,745
127,207
141,291
31,323
129,192
126,156
123,166
51,929
127,484
127,311
105,426
100,392
100,392105,426127,311127,48451,929123,166126,156129,19231,323141,291127,207134,74522,933125,854132,346131,22334,670123,141134,560119,97931,20285,30675,84666,00319,05587,80777,45071,262042,66546,29553,03255,76564,38264,47321,21521,62418,85518,15527,49117,15916,26614,22214,45416,82215,04522,53615,714
       Other Current Liabilities 
1,431
1,072
1,812
46
1,744
6,336
9,476
1,395
3,710
6,815
5,046
1,723
7,706
12,776
14,496
35,000
4,536
19,252
19,396
81,658
21,892
24,431
24,136
66,313
24,608
26,270
14,873
69,401
632
365
416
79,331
813
2,349
1,625
77,994
849
3,768
6,400
95,420
9,397
12,910
17,068
77,581
480
422
485
367
36748542248077,58117,06812,9109,39795,4206,4003,76884977,9941,6252,34981379,33141636563269,40114,87326,27024,60866,31324,13624,43121,89281,65819,39619,2524,53635,00014,49612,7767,7061,7235,0466,8153,7101,3959,4766,3361,744461,8121,0721,431
   > Long-term Liabilities 
5,152
5,152
5,152
5,659
5,408
5,217
5,168
4,449
3,596
3,526
4,638
5,500
5,499
121,658
121,709
109,016
109,043
108,566
98,940
103,791
101,909
91,822
97,041
103,716
104,564
128,520
148,839
132,892
132,879
141,498
150,968
150,609
154,713
157,010
219,871
264,290
268,299
286,531
313,051
309,818
327,822
326,084
314,577
302,106
295,476
284,482
375,917
491,707
491,707375,917284,482295,476302,106314,577326,084327,822309,818313,051286,531268,299264,290219,871157,010154,713150,609150,968141,498132,879132,892148,839128,520104,564103,71697,04191,822101,909103,79198,940108,566109,043109,016121,709121,6585,4995,5004,6383,5263,5964,4495,1685,2175,4085,6595,1525,1525,152
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
208,410
253,281
257,254
275,643
299,797
297,797
316,703
315,374
308,069
294,601
283,996
272,275
362,677
0
0362,677272,275283,996294,601308,069315,374316,703297,797299,797275,643257,254253,281208,4100000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,664
5,952
0
9,928
0
0
009,92805,9524,664000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
8,000
9,000
7,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000007,0009,0008,0000000000000000
> Total Stockholder Equity
171,153
162,923
169,365
170,503
177,203
187,892
180,103
182,649
191,014
179,800
188,483
193,630
204,763
190,243
448,182
449,718
457,561
446,721
453,062
454,516
464,382
462,575
473,980
479,865
490,647
486,275
500,076
481,041
498,094
503,732
508,416
529,750
541,042
583,942
594,421
643,821
638,783
613,843
612,336
624,004
635,471
638,106
643,983
655,222
668,841
673,903
674,520
687,123
687,123674,520673,903668,841655,222643,983638,106635,471624,004612,336613,843638,783643,821594,421583,942541,042529,750508,416503,732498,094481,041500,076486,275490,647479,865473,980462,575464,382454,516453,062446,721457,561449,718448,182190,243204,763193,630188,483179,800191,014182,649180,103187,892177,203170,503169,365162,923171,153
   Common Stock
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
139,478
139,478
139,478
139,478
139,478
139,478
139,478
139,478
139,478
333,684
333,684
333,684
347,188
347,188
347,188
347,188
369,059
374,404
374,404
374,404
404,922
404,922
404,922
405,857
405,857
405,856
405,856
419,367
419,367
419,367
419,367
432,466
432,466
432,466
432,466432,466432,466419,367419,367419,367419,367405,856405,856405,857405,857404,922404,922404,922374,404374,404374,404369,059347,188347,188347,188347,188333,684333,684333,684139,478139,478139,478139,478139,478139,478139,478139,478139,47869,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,739
   Retained Earnings 
102,992
94,762
87,484
88,622
95,322
106,011
98,222
100,768
109,133
97,919
106,602
111,749
120,718
106,198
114,500
116,757
124,585
113,183
119,409
121,266
130,830
129,313
140,440
145,596
156,243
166,582
152,686
161,075
175,411
189,308
177,746
182,946
196,507
227,611
203,989
220,182
237,796
210,824
224,253
239,972
260,263
259,622
271,209
288,370
311,003
306,402
310,563
319,065
319,065310,563306,402311,003288,370271,209259,622260,263239,972224,253210,824237,796220,182203,989227,611196,507182,946177,746189,308175,411161,075152,686166,582156,243145,596140,440129,313130,830121,266119,409113,183124,585116,757114,500106,198120,718111,749106,60297,919109,133100,76898,222106,01195,32288,62287,48494,762102,992
   Capital Surplus 000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
-1,578
-1,578
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
14,306
14,306
194,204
193,483
193,498
194,060
194,175
193,772
194,074
193,784
194,062
585
720
-13,991
202
-27,222
-24,505
-32,764
-38,389
-27,600
-29,869
-18,073
-14,490
18,717
-3,935
-2,838
-17,774
-21,824
-30,648
-40,883
-46,593
-52,515
-61,529
-64,965
-68,509
0
0-68,509-64,965-61,529-52,515-46,593-40,883-30,648-21,824-17,774-2,838-3,93518,717-14,490-18,073-29,869-27,600-38,389-32,764-24,505-27,222202-13,991720585194,062193,784194,074193,772194,175194,060193,498193,483194,20414,30614,30612,14212,14212,14212,14212,14212,14212,14212,14212,14212,142-1,578-1,578



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in MYR. All numbers in thousands.




Income Statement

Currency in MYR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue704,727
Cost of Revenue-436,401
Gross Profit268,326268,326
 
Operating Income (+$)
Gross Profit268,326
Operating Expense-186,814
Operating Income81,51281,512
 
Operating Expense (+$)
Research Development0
Selling General Administrative189,465
Selling And Marketing Expenses0
Operating Expense186,814189,465
 
Net Interest Income (+$)
Interest Income1,934
Interest Expense-18,197
Other Finance Cost-3,625
Net Interest Income-12,638
 
Pretax Income (+$)
Operating Income81,512
Net Interest Income-12,638
Other Non-Operating Income Expenses0
Income Before Tax (EBT)63,26799,757
EBIT - interestExpense = 63,315
63,267
70,842
Interest Expense18,197
Earnings Before Interest and Taxes (EBIT)81,51281,464
Earnings Before Interest and Taxes (EBITDA)120,526
 
After tax Income (+$)
Income Before Tax63,267
Tax Provision-10,276
Net Income From Continuing Ops61,30452,991
Net Income52,645
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses623,215
Total Other Income/Expenses Net-18,24512,638
 

Technical Analysis of Duopharma Biotech Bhd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Duopharma Biotech Bhd. The general trend of Duopharma Biotech Bhd is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Duopharma Biotech Bhd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Duopharma Biotech Bhd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.1621033333333 < 1.1621512605042 < 1.17.

The bearish price targets are: 1.14 > 1.0932 > 1.0813.

Tweet this
Duopharma Biotech Bhd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Duopharma Biotech Bhd. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Duopharma Biotech Bhd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Duopharma Biotech Bhd. The current macd is -0.00997351.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Duopharma Biotech Bhd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Duopharma Biotech Bhd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Duopharma Biotech Bhd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Duopharma Biotech Bhd Daily Moving Average Convergence/Divergence (MACD) ChartDuopharma Biotech Bhd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Duopharma Biotech Bhd. The current adx is 23.01.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Duopharma Biotech Bhd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Duopharma Biotech Bhd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Duopharma Biotech Bhd. The current sar is 1.14.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Duopharma Biotech Bhd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Duopharma Biotech Bhd. The current rsi is 52.13. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Duopharma Biotech Bhd Daily Relative Strength Index (RSI) ChartDuopharma Biotech Bhd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Duopharma Biotech Bhd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Duopharma Biotech Bhd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Duopharma Biotech Bhd Daily Stochastic Oscillator ChartDuopharma Biotech Bhd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Duopharma Biotech Bhd. The current cci is -4.55062571.

Duopharma Biotech Bhd Daily Commodity Channel Index (CCI) ChartDuopharma Biotech Bhd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Duopharma Biotech Bhd. The current cmo is 12.73.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Duopharma Biotech Bhd Daily Chande Momentum Oscillator (CMO) ChartDuopharma Biotech Bhd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Duopharma Biotech Bhd. The current willr is -37.5.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Duopharma Biotech Bhd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Duopharma Biotech Bhd Daily Williams %R ChartDuopharma Biotech Bhd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Duopharma Biotech Bhd.

Duopharma Biotech Bhd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Duopharma Biotech Bhd. The current atr is 0.02486748.

Duopharma Biotech Bhd Daily Average True Range (ATR) ChartDuopharma Biotech Bhd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Duopharma Biotech Bhd. The current obv is -781,900.

Duopharma Biotech Bhd Daily On-Balance Volume (OBV) ChartDuopharma Biotech Bhd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Duopharma Biotech Bhd. The current mfi is 28.58.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Duopharma Biotech Bhd Daily Money Flow Index (MFI) ChartDuopharma Biotech Bhd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Duopharma Biotech Bhd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Duopharma Biotech Bhd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Duopharma Biotech Bhd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.125
Ma 20Greater thanMa 501.186
Ma 50Greater thanMa 1001.194
Ma 100Greater thanMa 2001.214
OpenGreater thanClose1.160
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Duopharma Biotech Bhd with someone you think should read this too:
  • Are you bullish or bearish on Duopharma Biotech Bhd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Duopharma Biotech Bhd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Duopharma Biotech Bhd

I send you an email if I find something interesting about Duopharma Biotech Bhd.


Comments

How you think about this?

Leave a comment

Stay informed about Duopharma Biotech Bhd.

Receive notifications about Duopharma Biotech Bhd in your mailbox!